Michael Bruce is the founder of Exo Therapeutics. Exo Therapeutics has raised $78M in total funding. Latest round: Series B.
Michael Bruce is the CEO of Exo Therapeutics, a company developing small molecule drugs that target enzyme exosites to modulate enzyme activity. The startup, founded in 2018, aims to overcome challenges associated with traditional active site targeting, such as poor selectivity and side effects, by developing compounds that bind to exosites—distal binding pockets on enzymes. Exo Therapeutics has raised $78 million in Series B financing to advance its therapeutic candidates in oncology and inflammation derived from its proprietary ExoSight platform.
Full founder directory · Investor directory · Company funding database · Fundraising library